Obesity and Cardiovascular Diseases, Cross-sectional Study in Saudi Arabia

NCT05642533 | Completed

• 2 other identifiers: DAS-7510U1111-1279-3716
• Study Type: observational
• Target: 1,061
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this research study is to collect information on participants body weight, blood sugar levels, heart related diseases and lifestyle. The collected information will help estimate the prevalence of participants disease. This study will take about 6 months. However, participants involvement in the study will not extend beyond their routine visit and will thus require a maximum of 1 day. If participants choose to take part, they will be asked to give information about their health in routine clinical visit. Participants will be asked to complete a questionnaire about their lifestyle. Participants will complete this questionnaire during their normally scheduled visit with their doctor. Participants will continue their normal way of life and will not get any medication other than those prescribed to them by their doctor. Participants will have no direct benefit from participation in this study and there are no risks involved. Participants decide voluntarily whether they want to participate in this study or not. Participants' decision will not affect their medical care and they do not have to justify their decision. Participants are free to leave the study at any time and without giving reasons. This does not affect their current or future treatment. The data collected up to that point are still being evaluated. There is no additional cost to participants for being in this study.

Conditions

Obesity and Cardiovascular Risk

Outcome Measures

Primary Outcomes (1)

• Proportion of people with obesity without a history of Type 2 diabetes (T2D) who have Cardiovascular disease (CVD)s (pre-existing or newlydiagnosed)

  Percentage (and 95% confidence interval \[CI\])

  At time of patient enrollment/cross-sectional routine visit (DAY 1)

Study Arms (2)

Without a history of Type 2 diabetes

Adults with obesity

Other: No treatment given

With a history of Type 2 diabetes

Adults with obesity

Other: No treatment given

Interventions

No treatment given OTHER

No treatment given

With a history of Type 2 diabetes; Without a history of Type 2 diabetes

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population will include adults with obesity, either without a history of T2D (Cohort 1) or with a history of T2D (Cohort 2).

You may qualify if:

• Signed consent obtained before any study related activities (study related activities are any procedure-related to recording of data according to the protocol).
• Diagnosed with obesity (BMI higher than or equal to 30 for all ethnic groups except Asian; BMI higher than or equal to 27.5 for patients of Asian ethnicity).
• Diagnosed with T2D for patients in Cohort 2.
• Male or female, aged between 18 and 75 years at the time of signing informed consent

You may not qualify if:

• Participation in an interventional clinical trial during the study period.
• Diagnosed with T2D for patients in Cohort 1.
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Sponsors & Collaborators

• Novo Nordisk A/S: lead

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Clinical Transparency (dept. 2834)

  Novo Nordisk A/S

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 30, 2022
• First Posted: December 8, 2022
• Study Start: December 31, 2022
• Primary Completion: September 14, 2023
• Study Completion: September 14, 2023
• Last Updated: December 30, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will share